Table 1.
Characteristics of the patients
| Variable | Total |
|---|---|
| Total patients | 65 |
| Median Age (range) | 45 (11–73) |
| Male/female | 48/17 |
| Diagnosis | |
| AML | 47 |
| MDS | 5 |
| Lymphoma | 6 |
| CML | 2 |
| Other leukemia | 5 |
| Disease status before second HCT | |
| Remission | 13 |
| Not in remission | 52 |
| Donor status | |
| MRD | 33 |
| MUD | 21 |
| Haplo-cord | 11 |
| Conditioning regimen for first HCT | |
| Myeloablative | 19 |
| RIC | 46 |
| Conditioning regimen for second HCT | |
| Myeloablative | 44 |
| Flu-Bu-Alemtuzumab | 18 |
| TBI-based | 7 |
| Bu/Cy | 7 |
| RIC | 21 |
| Flu-mel-Alemtuzumab | 5 |
| Clo-mel-Alemtuzumab | 7 |
| Flu-mel-ATG | 7 |
MRD matched related donor, MUD matched unrelated donor, MDS myelodysplastic syndrome